14.19 USD
+0.51 (+3.73%)
At close: Feb 2, 2026
14.31 USD
+0.12 (+0.85%)
Pre-Market: 2/3/2026, 4:00:00 AM
Taking everything into account, AMRX scores 5 out of 10 in our fundamental rating. AMRX was compared to 191 industry peers in the Pharmaceuticals industry. Both the profitability and the financial health of AMRX get a neutral evaluation. Nothing too spectacular is happening here. A decent growth rate in combination with a cheap valuation! Better keep an eye on AMRX.
1. Profitability
1.1 Basic Checks
- In the past year AMRX was profitable.
- AMRX had a positive operating cash flow in the past year.
- In multiple years AMRX reported negative net income over the last 5 years.
- In the past 5 years AMRX always reported a positive cash flow from operatings.
1.2 Ratios
- AMRX's Return On Assets of 0.16% is fine compared to the rest of the industry. AMRX outperforms 77.49% of its industry peers.
- AMRX's Return On Invested Capital of 10.43% is amongst the best of the industry. AMRX outperforms 90.05% of its industry peers.
- AMRX had an Average Return On Invested Capital over the past 3 years of 7.98%. This is below the industry average of 12.82%.
- The 3 year average ROIC (7.98%) for AMRX is below the current ROIC(10.43%), indicating increased profibility in the last year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 0.16% | ||
| ROE | N/A | ||
| ROIC | 10.43% |
ROA(3y)-3.06%
ROA(5y)-1.33%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)7.98%
ROIC(5y)6.53%
1.3 Margins
- AMRX has a Profit Margin of 0.20%. This is in the better half of the industry: AMRX outperforms 77.49% of its industry peers.
- AMRX has a Operating Margin of 12.32%. This is amongst the best in the industry. AMRX outperforms 85.34% of its industry peers.
- In the last couple of years the Operating Margin of AMRX has grown nicely.
- AMRX's Gross Margin of 36.76% is fine compared to the rest of the industry. AMRX outperforms 60.21% of its industry peers.
- In the last couple of years the Gross Margin of AMRX has grown nicely.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 12.32% | ||
| PM (TTM) | 0.2% | ||
| GM | 36.76% |
OM growth 3Y6.45%
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-1.15%
GM growth 5Y4.39%
2. Health
2.1 Basic Checks
- With a Return on Invested Capital (ROIC) below the Cost of Capital (WACC), AMRX is destroying value.
- Compared to 1 year ago, AMRX has less shares outstanding
- The number of shares outstanding for AMRX has been increased compared to 5 years ago.
- AMRX has a better debt/assets ratio than last year.
2.2 Solvency
- An Altman-Z score of 1.97 indicates that AMRX is not a great score, but indicates only limited risk for bankruptcy at the moment.
- With a decent Altman-Z score value of 1.97, AMRX is doing good in the industry, outperforming 60.21% of the companies in the same industry.
- AMRX has a debt to FCF ratio of 11.13. This is a negative value and a sign of low solvency as AMRX would need 11.13 years to pay back of all of its debts.
- The Debt to FCF ratio of AMRX (11.13) is better than 78.53% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | N/A | ||
| Debt/FCF | 11.13 | ||
| Altman-Z | 1.97 |
ROIC/WACC1
WACC10.46%
2.3 Liquidity
- AMRX has a Current Ratio of 2.13. This indicates that AMRX is financially healthy and has no problem in meeting its short term obligations.
- AMRX's Current ratio of 2.13 is on the low side compared to the rest of the industry. AMRX is outperformed by 60.21% of its industry peers.
- A Quick Ratio of 1.42 indicates that AMRX should not have too much problems paying its short term obligations.
- With a Quick ratio value of 1.42, AMRX is not doing good in the industry: 65.44% of the companies in the same industry are doing better.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 2.13 | ||
| Quick Ratio | 1.42 |
3. Growth
3.1 Past
- The Earnings Per Share has grown by an impressive 25.00% over the past year.
- AMRX shows quite a strong growth in Earnings Per Share. Measured over the last years, the EPS has been growing by 10.63% yearly.
- Looking at the last year, AMRX shows a quite strong growth in Revenue. The Revenue has grown by 16.73% in the last year.
- Measured over the past years, AMRX shows a quite strong growth in Revenue. The Revenue has been growing by 11.43% on average per year.
EPS 1Y (TTM)25%
EPS 3Y-11.61%
EPS 5Y10.63%
EPS Q2Q%6.25%
Revenue 1Y (TTM)16.73%
Revenue growth 3Y10.1%
Revenue growth 5Y11.43%
Sales Q2Q%11.68%
3.2 Future
- The Earnings Per Share is expected to grow by 11.95% on average over the next years. This is quite good.
- AMRX is expected to show a small growth in Revenue. In the coming years, the Revenue will grow by 0.60% yearly.
EPS Next Y40.2%
EPS Next 2Y28.34%
EPS Next 3Y26.83%
EPS Next 5Y11.95%
Revenue Next Year8.74%
Revenue Next 2Y7.6%
Revenue Next 3Y7.79%
Revenue Next 5Y0.6%
3.3 Evolution
- The EPS growth rate is stable: in the next years the growth will be about the same than in the last years.
- When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
4. Valuation
4.1 Price/Earnings Ratio
- With a Price/Earnings ratio of 18.92, AMRX is valued on the expensive side.
- 82.72% of the companies in the same industry are more expensive than AMRX, based on the Price/Earnings ratio.
- AMRX's Price/Earnings ratio indicates a valuation a bit cheaper than the S&P500 average which is at 28.41.
- The Price/Forward Earnings ratio is 14.85, which indicates a correct valuation of AMRX.
- Based on the Price/Forward Earnings ratio, AMRX is valued cheaper than 83.25% of the companies in the same industry.
- When comparing the Price/Forward Earnings ratio of AMRX to the average of the S&P500 Index (25.64), we can say AMRX is valued slightly cheaper.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 18.92 | ||
| Fwd PE | 14.85 |
4.2 Price Multiples
- AMRX's Enterprise Value to EBITDA ratio is rather cheap when compared to the industry. AMRX is cheaper than 85.86% of the companies in the same industry.
- Based on the Price/Free Cash Flow ratio, AMRX is valued cheaply inside the industry as 85.86% of the companies are valued more expensively.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 18.86 | ||
| EV/EBITDA | 11.45 |
4.3 Compensation for Growth
- The low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
- The decent profitability rating of AMRX may justify a higher PE ratio.
- A more expensive valuation may be justified as AMRX's earnings are expected to grow with 26.83% in the coming years.
PEG (NY)0.47
PEG (5Y)1.78
EPS Next 2Y28.34%
EPS Next 3Y26.83%
5. Dividend
5.1 Amount
- No dividends for AMRX!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
14.19
+0.51 (+3.73%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)10-30 2025-10-30/bmo
Earnings (Next)02-27 2026-02-27/bmo
Inst Owners45.17%
Inst Owner Change-0.16%
Ins Owners46.29%
Ins Owner Change-4.23%
Market Cap4.46B
Revenue(TTM)2.93B
Net Income(TTM)5.90M
Analysts81.82
Price Target14.79 (4.23%)
Short Float %4.39%
Short Ratio3.8
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DP0%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)30.63%
Min EPS beat(2)21.21%
Max EPS beat(2)40.06%
EPS beat(4)3
Avg EPS beat(4)19.7%
Min EPS beat(4)-22.85%
Max EPS beat(4)40.37%
EPS beat(8)7
Avg EPS beat(8)26.2%
EPS beat(12)11
Avg EPS beat(12)30.21%
EPS beat(16)11
Avg EPS beat(16)19.73%
Revenue beat(2)0
Avg Revenue beat(2)-2.51%
Min Revenue beat(2)-4.6%
Max Revenue beat(2)-0.41%
Revenue beat(4)1
Avg Revenue beat(4)-2.13%
Min Revenue beat(4)-4.71%
Max Revenue beat(4)1.22%
Revenue beat(8)3
Avg Revenue beat(8)-0.67%
Revenue beat(12)7
Avg Revenue beat(12)0.45%
Revenue beat(16)8
Avg Revenue beat(16)-0.15%
PT rev (1m)3.57%
PT rev (3m)20.83%
EPS NQ rev (1m)-1.1%
EPS NQ rev (3m)1.75%
EPS NY rev (1m)-0.25%
EPS NY rev (3m)3.53%
Revenue NQ rev (1m)-0.03%
Revenue NQ rev (3m)-0.55%
Revenue NY rev (1m)0%
Revenue NY rev (3m)0.26%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 18.92 | ||
| Fwd PE | 14.85 | ||
| P/S | 1.52 | ||
| P/FCF | 18.86 | ||
| P/OCF | 13.61 | ||
| P/B | N/A | ||
| P/tB | N/A | ||
| EV/EBITDA | 11.45 |
EPS(TTM)0.75
EY5.29%
EPS(NY)0.96
Fwd EY6.73%
FCF(TTM)0.75
FCFY5.3%
OCF(TTM)1.04
OCFY7.35%
SpS9.34
BVpS-0.35
TBVpS-4.11
PEG (NY)0.47
PEG (5Y)1.78
Graham NumberN/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 0.16% | ||
| ROE | N/A | ||
| ROCE | 13.2% | ||
| ROIC | 10.43% | ||
| ROICexc | 11.26% | ||
| ROICexgc | 21.11% | ||
| OM | 12.32% | ||
| PM (TTM) | 0.2% | ||
| GM | 36.76% | ||
| FCFM | 8.06% |
ROA(3y)-3.06%
ROA(5y)-1.33%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)7.98%
ROIC(5y)6.53%
ROICexc(3y)8.26%
ROICexc(5y)6.86%
ROICexgc(3y)18.59%
ROICexgc(5y)15.87%
ROCE(3y)10.57%
ROCE(5y)8.54%
ROICexgc growth 3Y25.12%
ROICexgc growth 5YN/A
ROICexc growth 3Y27.15%
ROICexc growth 5YN/A
OM growth 3Y6.45%
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-1.15%
GM growth 5Y4.39%
F-Score7
Asset Turnover0.82
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | N/A | ||
| Debt/FCF | 11.13 | ||
| Debt/EBITDA | 4.36 | ||
| Cap/Depr | 37.95% | ||
| Cap/Sales | 3.11% | ||
| Interest Coverage | 1.67 | ||
| Cash Conversion | 54.45% | ||
| Profit Quality | 4008.53% | ||
| Current Ratio | 2.13 | ||
| Quick Ratio | 1.42 | ||
| Altman-Z | 1.97 |
F-Score7
WACC10.46%
ROIC/WACC1
Cap/Depr(3y)33.21%
Cap/Depr(5y)30.06%
Cap/Sales(3y)3.22%
Cap/Sales(5y)3.1%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)25%
EPS 3Y-11.61%
EPS 5Y10.63%
EPS Q2Q%6.25%
EPS Next Y40.2%
EPS Next 2Y28.34%
EPS Next 3Y26.83%
EPS Next 5Y11.95%
Revenue 1Y (TTM)16.73%
Revenue growth 3Y10.1%
Revenue growth 5Y11.43%
Sales Q2Q%11.68%
Revenue Next Year8.74%
Revenue Next 2Y7.6%
Revenue Next 3Y7.79%
Revenue Next 5Y0.6%
EBIT growth 1Y26.75%
EBIT growth 3Y17.2%
EBIT growth 5YN/A
EBIT Next Year13.18%
EBIT Next 3Y10.07%
EBIT Next 5Y3.87%
FCF growth 1Y72%
FCF growth 3Y5.18%
FCF growth 5YN/A
OCF growth 1Y75.78%
OCF growth 3Y6.86%
OCF growth 5Y180.48%
AMNEAL PHARMACEUTICALS INC / AMRX FAQ
What is the fundamental rating for AMRX stock?
ChartMill assigns a fundamental rating of 5 / 10 to AMRX.
What is the valuation status for AMRX stock?
ChartMill assigns a valuation rating of 8 / 10 to AMNEAL PHARMACEUTICALS INC (AMRX). This can be considered as Undervalued.
How profitable is AMNEAL PHARMACEUTICALS INC (AMRX) stock?
AMNEAL PHARMACEUTICALS INC (AMRX) has a profitability rating of 6 / 10.
How financially healthy is AMNEAL PHARMACEUTICALS INC?
The financial health rating of AMNEAL PHARMACEUTICALS INC (AMRX) is 4 / 10.
Can you provide the expected EPS growth for AMRX stock?
The Earnings per Share (EPS) of AMNEAL PHARMACEUTICALS INC (AMRX) is expected to grow by 40.2% in the next year.